Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Dihydrotestosterone in adult fish and frogs br New perspe
2023-09-21

Dihydrotestosterone in adult fish and frogs New perspectives and next directions Similar to other androgens, DHT can modulate reproductive endpoints in both fish and amphibians. However, predicting the effects of DHT can be challenging, as reproductive homeostasis is dependent upon the balance
-
TDZD-8 Steroidal CYP inhibitors can further be
2023-09-21

Steroidal CYP17 inhibitors can further be classified based on their mode of action, namely as mechanism-based inhibitors and type I and type II competitive inhibitors [129]. Recent studies investigated other biological targets than CYP17, and some new compounds have shown interesting dual activity a
-
dna ligase Our outcrossing data confirmed that
2023-09-21

Our outcrossing data confirmed that ACL1 and ACL2 have important temporal and spatial functions in ascospore delimitation in G. zeae. When each ACL deletion mutant was used as male for outcrossing, nuclear division and spore delimitation were not properly progressed in most asci. Ascospores that con
-
This project was funded by the University of the Philippines
2023-09-21

This project was funded by the University of the Philippines Diliman through the Natural Sciences Research Institute with grant No. CHE-09-2-02. Introduction There is compelling evidence for an anti-inflammatory effect of 12- and 15-lipoxygenases through the generation of lipid mediators involve
-
Plasma apelin levels predict the major cardiovascular event
2023-09-21

Plasma apelin levels predict the major cardiovascular event after percutaneous coronary intervention in patients with ST elevation myocardial infarction (STEMI), and adverse events are higher in patients with lower plasma apelin levels [75]. Apelin and its receptor are markedly upregulated in the he
-
br Telmisartan Telmisartan is one of the widely used
2023-09-21

Telmisartan Telmisartan is one of the widely used antihypertensive agents, which has demonstrated favorable safety and tolerability profiles, both alone and in combination therapies. It has a number of pharmacological properties that distinguish it from other ARBs—the longest plasma half-life, hi
-
br Funding This study was
2023-09-21

Funding This study was supported by a grant from the Science and Technology Program of Guangzhou (No. 2014Y2-00181) and the personnel training program of Southern Medical University (No. PY2015N023). Conflict of interest statement Authors’contributions Introduction Chronic cerebral hypo
-
fosaprepitant dimeglumine synthesis Accumulating evidence su
2023-09-20

Accumulating evidence suggest that patients with advanced -positive NSCLC are at increased risk of VTE or coagulation disorders during the course of their disease, indicating that cancer genotype might play a role in the occurrence of cancer-related thromboembolism . Here we report the case of a pat
-
br Current therapies for metabolic diseases
2023-09-20

Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m
-
Jesus et al discovered a new
2023-09-20

Jesus et al. discovered a new series of azaindole as Aurora inhibitors through various modification of GSK1070916 (47). They synthesized series from modification of the GSK1070916 and evaluated for in-vitro Aurora-B/INCENP and Aurora-A/TPX2 inhibition assays. Modified Chlorpromazine HCl 48 and 49 s
-
br The role of apelin in hepatic diseases
2023-09-20

The role of apelin in hepatic diseases The involvement of the apelin/APJ system in liver physiology and pathology has been proven in numerous studies (Table 6). For instance, in the experiment of Emam et al. [63] on rats suffering from hepatic injury, apelin decreased the levels of ALT, AST and L
-
br Apelin Discovered in apelin was
2023-09-20

Apelin Discovered in 1998, apelin was initially identified as the sole endogenous ligand for the APJ receptor (Tatemoto et al., 1998). Apelin-77 (pre-pro-apelin) is the precursor for various pharmacologically active apelin isoforms (e.g. apelin-12, -13, -17 and 36), and it shares 75–95% sequence
-
Because antioxidants have a strong radical scavenging effici
2023-09-20

Because antioxidants have a strong radical scavenging efficiency, a mixture of H2O2 and antioxidants should exhibit a much weaker depolymerization process than H2O2 alone. Therefore, we expected the redox behavior of silver could be affected by the presence of the antioxidant. The schematic diagram
-
The renin angiotensin system RAS
2023-09-20

The renin-angiotensin system (RAS) is a hormonal system which plays a role in the regulation of blood pressure and body fluid Hoechst 34580 [14]. The main bioactive peptide of RAS is angiotensin II (Ang II) whose biological functions are interposed through angiotensin type 1 receptor (AT1R) and ang
-
br Development of lorlatinib from crizotinib to a clinical
2023-09-19

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
16349 records 301/1090 page Previous Next First page 上5页 301302303304305 下5页 Last page